|
|
Albert Bourla, the CEO and top salesman of Pfizer, said Sunday that the U.S. will need a fourth dose of the COVID-19 vaccine due to the threat of new variants and the drug’s loss of effectiveness over time.
“It is necessary, a fourth (dose) for right now,” Bourla, who made $21 million in total compensation in 2020, told CBS’ “Face the Nation.”
Bourla told the network that Pfizer just submitted data to the Food and Drug Administration for approval. He said the company’s goal is to come up with a vaccine that is effective for “at least a year.”
“And if we are able to achieve that, then I think it is very easy to follow and remember so that we can go back to really the way (we) used to live,” Bourla said.
The Trends Journal has reported on how COVID-19 vaccines have proven to be the most lucrative product in history and has made drug-lord billionaires. (See “PFIZER DRUG LORD PUSHING YEARLY COVID JABS. CALLS THOSE WHO WON’T SWALLOW BULLSHIT, ‘CRIMINALS,’” “JAB KIDS WHO WON’T DIE OF THE VIRUS: THERE’S NO BUSINESS LIKE THE VAX BUSINESS” and “MORE COVID JABS, MORE BIG BUCKS FOR DRUG LORDS.”)
Bourla said the protection from the third shot is still good enough to prevent hospitalizations and deaths.
“It’s not that good against infections but doesn’t last very long. But we are just submitting those data to the FDA, and then we will see what the experts also will say outside Pfizer,” he said.
Israel and other countries have already recommended the fourth dose for some groups.
TRENDPOST: As for the efficacy of the Operation Warp Speed inoculation? When it was hawked to the public back in 2020, it was sold that two shots would have 95 percent efficacy rate. However, according to the Israeli health ministry back in July 2021, that number has shrunk to 39 percent. And now two shots won’t do the job… it’s doubled up to four. Yet, there is not a mention of this in the mainstream media.
Vaccine Gold Mine
Moderna and Pfizer say they will earn a combined $51 billion in vaccine sales in 2022, despite the drop of infections in many parts of the world, CNBC reported.
The report, citing fourth-quarter earnings statements released by the companies last month, said Pfizer expects to pull in $32 billion in vaccine sales and Moderna believes it will sell at least $19 billion.
Moderna CEO Stéphane Bancel pulled in $18.2 million in cash, stock, and options last year, according to Barron’s. The amount is more than double what he earned in 2019, prior to the COVID-19 outbreak. His pay spike comes as the Massachusetts biotech company generated $18.5 billion in revenues last year, FiercePharma.com reported.
CNBC reported that Moderna’s board showed its appreciation to the sales increase and approved a “golden parachute” for the CEO that amounts to more than $926 million—most tied to company stock.
TREND FORECAST: Just like the flu shots, a sizable number of fearful people will get a yearly COVID Vax shot.
Furthermore, the drug dealers plan to develop vaccines that target particular variants of COVID-19, and people could be encouraged to get them annually, on the model of flu shots.
Trends Journal reported in “DRUG COMPANIES CASHING IN ON COVID” (11 May 2021) that Pfizer considers COVID-19 as providing a “durable revenue stream.”
Here We Go Again…New Variant Discovered in Europe
A new coronavirus variant—dubbed Deltacron—has been discovered in European countries and is being investigated by scientists who currently believe there is no change in severity.
The variant is considered a hybrid that combines both the Delta and Omicron variants that have already spread throughout the world. Reuters reported that there have been 17 confirmed cases in France, the Netherlands, and Denmark.
Maria Van Kerkhove, a World Health Organization COVID-19 technical lead, said scientists have not seen “any change in the epidemiology with this recombinant.”
“We haven’t seen any change in severity. But there are many studies that are underway,” she said, according to Reuters. The WHO has not called Deltacron a variant of concern.
Dr. John Swartzberg, a professor of infectious diseases at the University of California, said the name Deltacron invokes worry because people likely remember the Delta variant as being more severe and Omicron being more contagious.
“There is absolutely no evidence that this new recombinant virus has those qualities at all,” he said.
TRENDPOST: Deltacron gives politicians and their mouthpieces in corporate media the opportunity to scare the public again to drive up ratings and make a fourth jab being sold by drug companies all the more reasonable. COVID-19 has been the pandemic of fear because our “leaders” know that a public that is frightened is a public that can be controlled.